Koers Miragen Therapeutics Inc Nasdaq
Aandelen
US8266402036
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
|
11/06 | Sectorupdate: Gezondheidszorgaandelen dinsdag premarket gemengd | MT |
11/06 | Sectorupdate: Gezondheidszorg | MT |
Omzet 2024 * | 349K 321K | Omzet 2025 * | 305K 280K | Marktkapitalisatie | 938 mln. 861 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -230 mln. -211 mln. | Nettowinst (verlies) 2025 * | -270 mln. -248 mln. | EV/omzet 2024 * | 1.361 x |
Nettoliquiditeiten 2024 * | 462 mln. 425 mln. | Nettoliquiditeiten 2025 * | 625 mln. 574 mln. | EV/omzet 2025 * | 1.025 x |
K/w-verhouding 2024 * |
-3,96
x | K/w-verhouding 2025 * |
-3,68
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 94,26% |
Recentste transcriptie over Miragen Therapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 30-10-23 |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 01-05-23 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 01-01-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 03-01-18 |
Tomas Kiselak
CHM | Chairman | 37 | 28-10-20 |
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 30-10-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,20% | 46,56 mld. | |
+45,38% | 41,67 mld. | |
+0,27% | 41,16 mld. | |
+33,67% | 32,4 mld. | |
+20,80% | 28,18 mld. | |
-6,35% | 28,1 mld. | |
+49,19% | 14,52 mld. | |
+47,51% | 13,74 mld. | |
+3,07% | 12,17 mld. |
- Beurs
- Aandelen
- Koers VRDN
- Koers